As part of the new collaboration, the two companies will work together to co-create the candidate for the oncology target, leveraging PepMetics technology. Once the development candidate is
This acceptance will allow GSK to potentially expand the use of Jemperli for the treatment of primary advanced or recurrent endometrial cancer in all the adult patients, including
As part of this strategic partnership, the two companies aim to leverage their shared technology as well as clinical development resources to create synergies in therapeutics development. The
The deal, valued at up to $380m, includes upfront and milestone payments. Under the terms of the agreement, Cellares will streamline, automate, and transfer technology for selected BMS
Merck, referred as MSD outside the US and Canada, has confirmed that Health Canada has approved a new indication for PREVYMIS (letermovir) to prevent cytomegalovirus (CMV) disease in
This partnership follows the US Food and Drug Administration’s approval of ADSTILADRIN in December 2022 for adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC)
This partnership is set to enhance the treatment options available to diabetes patients in Brazil. Under the agreement, Biocon will be responsible for the development, manufacturing, and supply
A product of BioCryst Pharmaceuticals, Orladeyo’s registration, commercialisation and distribution are solely handled by Pint Pharma in Latin America. Hereditary angioedema (HAE) is a genetic disorder characterised by
The designation is specifically for the characterisation of progressive or recurrent glioma using positron emission tomography (PET). TLX101-CDx is a PET imaging agent that targets membrane transport proteins
The company also plans to implement additional measures. This decision comes as the company seeks to extend its cash runway available and reassess its capital raising options in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.